Topic

Articles

Strong economic data in other sectors mean rising ‘real’ rates.

No Rate Relief in Sight for Biotech 

Could the sector be nearing a turning point in performance?

More Evidence is  Pointing to Potential Swing for Biotech

New executive brings over 30 years of experience in the biopharma industry. 

Jami Rubin Announced as Boundless Bio Chief Financial Officer 

But will Washington’s dealmaking stance upend the momentum?

Shifting Macro Trends Offer Hope for Biotech Performance Boost

Ira Studin, PhD, MPH, is president of Stellar Managed Care Consulting, a pharma busines strategies firm in Cherry Hill, New Jersey. He has written Strategic Healthcare Management and numerous articles in healthcare business journals. He can be reached at istudin@stellarmc.com

Conditions require a disciplined approach to drug pricing. 

‘Bolus’ Markets: Unique Business Opportunities with Promise and Risk

Chief Advocacy and Engagement Officer, PAN Foundation

The Medicare Part D cap won’t solve need for financial assistance.

The Quest to Fully Address Prescription Drug Affordability

Such a scenario is one possibility as the bear market languishes on.

Could a Rates Pivot By Fed Change Biotech’s Fate? 

Brent Herspiegel is the CEO of Herspiegel Consulting.

Beth Schurman is the COO of Herspiegel Consulting.

When deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.

When to Utilize Commercial Outsourcing 

The ‘blistering’ pace may further divide the haves from the have-nots.

Will Recent Surge in M&A Dealmaking Save Biotech Sector?

Over two years into a bear market, it still can’t catch a sustainable bid.

Finance